Biontech Se (BNTX)

$88.49

+0.48

(+0.55%)▲

Market is closed - opens 7 PM, 24 Apr 2024

Insights on Biontech Se

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 167.7M → 1.47B (in $), with an average increase of 60.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -190.4M → 457.9M (in $), with an average increase of 141.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 70.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 287.4%

Performance

  • $87.76
    $89.44
    $88.49
    downward going graph

    0.82%

    Downside

    Day's Volatility :1.87%

    Upside

    1.06%

    downward going graph
  • $85.21
    $125.83
    $88.49
    downward going graph

    3.71%

    Downside

    52 Weeks Volatility :32.28%

    Upside

    29.67%

    downward going graph

Returns

PeriodBiontech SeSector (Health Care)Index (Russel 2000)
3 Months
-12.24%
-0.4%
0.0%
6 Months
-4.87%
9.6%
0.0%
1 Year
-24.73%
3.9%
-1.3%
3 Years
-49.13%
12.8%
-22.1%

Highlights

Market Capitalization
20.9B
Book Value
$85.17
Earnings Per Share (EPS)
4.09
PE Ratio
21.22
PEG Ratio
0.04
Wall Street Target Price
118.43
Profit Margin
24.36%
Operating Margin TTM
40.0%
Return On Assets TTM
2.62%
Return On Equity TTM
4.62%
Revenue TTM
3.8B
Revenue Per Share TTM
15.87
Quarterly Revenue Growth YOY
-65.4%
Gross Profit TTM
16.1B
EBITDA
1.1B
Diluted Eps TTM
4.09
Quarterly Earnings Growth YOY
-0.79
EPS Estimate Current Year
-2.07
EPS Estimate Next Year
-1.45
EPS Estimate Current Quarter
2.63
EPS Estimate Next Quarter
-0.43

Analyst Recommendation

Buy
    60%Buy
    39%Hold
    0
    0%Sell
Based on 23 Wall street analysts offering stock ratings for Biontech Se(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
16
16
Hold
9
7
7
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 33.83%

Current $88.49
Target $118.43

Company Financials

FY18Y/Y Change
Revenue
146.0M
↑ 107.11%
Net Income
-54.9M
↓ 43.94%
Net Profit Margin
-37.64%
↑ 101.41%
FY19Y/Y Change
Revenue
121.6M
↓ 14.88%
Net Income
-200.7M
↑ 273.13%
Net Profit Margin
-165.0%
↓ 127.36%
FY20Y/Y Change
Revenue
593.3M
↑ 344.17%
Net Income
18.7M
↓ 108.48%
Net Profit Margin
3.15%
↑ 168.15%
FY21Y/Y Change
Revenue
21.5B
↑ 3834.42%
Net Income
11.7B
↑ 67613.82%
Net Profit Margin
54.24%
↑ 51.09%
FY22Y/Y Change
Revenue
18.5B
↓ 8.78%
Net Income
10.1B
↓ 8.34%
Net Profit Margin
54.5%
↑ 0.26%
FY23Y/Y Change
Revenue
3.8B
↓ 77.94%
Net Income
930.3M
↓ 90.14%
Net Profit Margin
24.36%
↓ 30.14%
Q3 FY22Q/Q Change
Revenue
3.4B
↑ 8.28%
Net Income
1.8B
↑ 6.75%
Net Profit Margin
51.57%
↓ 0.74%
Q4 FY22Q/Q Change
Revenue
4.6B
↑ 23.61%
Net Income
2.4B
↑ 27.67%
Net Profit Margin
53.26%
↑ 1.69%
Q1 FY23Q/Q Change
Revenue
1.4B
↓ 70.15%
Net Income
547.7M
↓ 77.96%
Net Profit Margin
39.33%
↓ 13.93%
Q2 FY23Q/Q Change
Revenue
183.0M
↓ 86.87%
Net Income
-207.7M
↓ 137.91%
Net Profit Margin
-113.54%
↓ 152.87%
Q3 FY23Q/Q Change
Revenue
895.3M
↑ 433.87%
Net Income
160.6M
↓ 184.35%
Net Profit Margin
17.94%
↑ 131.48%
Q4 FY23Q/Q Change
Revenue
1.5B
↑ 65.2%
Net Income
457.9M
↑ 185.12%
Net Profit Margin
30.96%
↑ 13.02%
FY18Y/Y Change
Total Assets
747.0M
↑ 74.26%
Total Liabilities
441.6M
↓ 8.73%
FY19Y/Y Change
Total Assets
893.5M
↑ 22.15%
Total Liabilities
340.7M
↓ 21.2%
FY20Y/Y Change
Total Assets
2.9B
↑ 190.68%
Total Liabilities
1.2B
↑ 211.28%
FY21Y/Y Change
Total Assets
17.9B
↑ 582.77%
Total Liabilities
4.5B
↑ 315.84%
FY22Y/Y Change
Total Assets
24.9B
↑ 47.05%
Total Liabilities
3.5B
↓ 18.13%
FY23Y/Y Change
Total Assets
23.0B
↓ 1.17%
Total Liabilities
2.8B
↓ 14.37%
Q3 FY22Q/Q Change
Total Assets
22.3B
↑ 7.11%
Total Liabilities
4.2B
↓ 0.7%
Q4 FY22Q/Q Change
Total Assets
24.9B
↑ 2.73%
Total Liabilities
3.5B
↓ 24.94%
Q1 FY23Q/Q Change
Total Assets
24.1B
↓ 5.16%
Total Liabilities
2.0B
↓ 43.74%
Q2 FY23Q/Q Change
Total Assets
24.3B
↑ 0.66%
Total Liabilities
2.5B
↑ 27.87%
Q3 FY23Q/Q Change
Total Assets
22.2B
↓ 0.08%
Total Liabilities
2.3B
↑ 0.92%
Q4 FY23Q/Q Change
Total Assets
23.0B
↑ 3.6%
Total Liabilities
2.8B
↑ 17.95%
FY18Y/Y Change
Operating Cash Flow
-66.6M
↑ 10.69%
Investing Cash Flow
-76.0M
↑ 26.46%
Financing Cash Flow
417.8M
↓ 22326.23%
FY19Y/Y Change
Operating Cash Flow
-222.4M
↑ 241.25%
Investing Cash Flow
-86.4M
↑ 16.05%
Financing Cash Flow
429.4M
↑ 4.96%
FY20Y/Y Change
Operating Cash Flow
-16.6M
↓ 93.21%
Investing Cash Flow
-178.2M
↑ 87.83%
Financing Cash Flow
1.1B
↑ 133.43%
FY21Y/Y Change
Operating Cash Flow
1.0B
↓ 6703.09%
Investing Cash Flow
-641.1M
↑ 290.82%
Financing Cash Flow
106.7M
↓ 89.47%
Q3 FY22Q/Q Change
Operating Cash Flow
4.7B
↑ 21.94%
Investing Cash Flow
-81.9M
↑ 6.25%
Financing Cash Flow
-642.3M
↓ 16.39%
Q4 FY22Q/Q Change
Operating Cash Flow
888.3M
↓ 82.65%
Investing Cash Flow
-1.3B
↑ 1379.23%
Financing Cash Flow
-69.3M
↓ 90.1%
Q1 FY23Q/Q Change
Operating Cash Flow
-738.7M
↓ 181.69%
Investing Cash Flow
-1.3B
↑ 0.0%
Financing Cash Flow
-317.7M
↑ 350.23%
Q2 FY23Q/Q Change
Operating Cash Flow
4.8B
↓ 747.58%
Investing Cash Flow
-1.3B
↑ 0.0%
Financing Cash Flow
-178.3M
↓ 43.91%
Q3 FY23Q/Q Change
Operating Cash Flow
811.2M
↓ 81.51%
Investing Cash Flow
-1.2B
↑ 0.0%
Financing Cash Flow
-311.0M
↑ 90.33%

Technicals Summary

Sell

Neutral

Buy

Biontech Se is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biontech Se
Biontech Se
-5.37%
-4.87%
-24.73%
-49.13%
518.05%
Moderna, Inc.
Moderna, Inc.
-5.36%
32.83%
-24.38%
-39.84%
322.91%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.34%
13.15%
12.94%
84.22%
161.57%
Novo Nordisk A/s
Novo Nordisk A/s
-2.94%
28.97%
46.95%
238.27%
414.84%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.87%
8.77%
20.15%
83.53%
128.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biontech Se
Biontech Se
21.22
21.22
0.04
-2.07
0.05
0.03
NA
85.17
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.77
25.77
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.13
46.13
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.39
28.39
0.53
16.72
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biontech Se
Biontech Se
Buy
$20.9B
518.05%
21.22
24.36%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
322.91%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.4B
161.57%
25.77
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.3B
414.84%
46.13
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
128.04%
28.39
36.68%

Institutional Holdings

  • Baillie Gifford & Co Limited.

    3.66%

  • PRIMECAP Management Company

    2.00%

  • Temasek Holdings Ltd.

    1.90%

  • Harding Loevner L.P.

    1.66%

  • Flossbach von Storch AG

    1.49%

  • BlackRock Inc

    0.66%

Corporate Announcements

  • Biontech Se Dividends September,2022

    In the quarter ending September,2022. Biontech Se has declared dividend of $2.11

    Read More

Company Information

everyone achieves greatness at biontech! as one of the most rapidly growing biotechnology companies in europe, we’re working on revolutionary approaches in the fight against cancer and other diseases. over 400 dedicated, passionate pioneers achieve sensational success and promising breakthroughs time and again by forging new paths – and ensure people all around the world have hope for the future. you too can become a pioneer! http://biontech.de/ http://biontech.de/imprint/

Organization
Biontech Se
Employees
6133
CEO
Dr. Ugur Sahin M.D.
Industry
Health Technology

Discover More

FAQs